Biotech

Tharimmune (THAR) announced a $1.74 million registered direct offering consisting of common stock and warrants. Units are priced at $1.786, including one share or pre-funded warrant and a common warrant. President Street Global is the placement agent. Proceeds will fund working capital and general corporate purposes. The offering is expected to close around July 25, 2025. This funding aims to support Tharimmune’s work in immunology and inflammation therapies, including their clinical asset, TH104.

Quince Therapeutics announced a securities purchase agreement to raise approximately $11.5 million upfront, with the potential for an additional $10.4 million if warrants are exercised. The financing, priced at a premium, will fund working capital, R&D, and general corporate purposes, extending its operational runway into Q2 2026 (or potentially H2 2026). The placement is led by Nantahala Capital and is set to close in June 2025.

Bicara Therapeutics (BCAX) will present at the Goldman Sachs 46th Annual Global Healthcare Conference. Management will host a fireside chat on June 10th to discuss the company’s strategy and pipeline. The presentation will focus on their clinical-stage bifunctional therapies, particularly their lead program, ficerafusp alfa, designed to treat solid tumors by overcoming challenges in the tumor microenvironment. A webcast replay will be available.

Defense Therapeutics Inc. announced the opening of its first U.S. lab in the Boston-Cambridge area. This strategic move expands its R&D efforts within a leading biotech hub, focusing on the Accum® platform for antibody-drug conjugates (ADCs) used in cancer treatment. The Watertown facility provides access to crucial scientific resources and collaboration opportunities. Defense Therapeutics aims to establish a long-term presence in the area, aiming to strengthen its commitment to advancing their platform.

Taysha Gene Therapies (TSHA) announced a public offering to raise approximately $200 million. The offering includes common stock and pre-funded warrants, priced at $2.75 and $2.749 per share respectively. This capital will advance Taysha’s CNS-focused gene therapy programs, targeting diseases like Rett syndrome with its AAV-based therapies. The deal is expected to close around May 30, 2025.